The veterinary diagnostic imaging market is set to reach from US$ 1,931.5 Mn in 2017 to US$ 3,473.9 Mn by 2026 at a compound annual growth rate (CAGR) of 6.8% during the forecast period from 2018 to 2026. Veterinary diagnostic imaging is a non-invasive procedure which is employed to obtain medical images of animals suffering with acute and chronic diseases.
The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2033. Cervical cancer occurs in women in age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer which is sexually transmitted.
The bispecific antibodies market is set to grow with a compounded annual growth rate (CAGR) of 5.9% during the forecast period from 2021 to 2029. According to the research findings presented by the World Health Organization (WHO), in 2021 cancer is responsible for the death of approximately 9.6 million people throughout the globe. The severe adverse effects related to chemotherapy led to the development of bispecific antibodies for the treatment of cancer.
T-cell lymphoma treatment market accounted for a market value of US$ 1300.8 Mn in 2021 and projected to grow at a CAGR of 11.7% during the forecast period from 2025 to 2033. Lymphoma is divided into two types Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphoma is segmented as B-cell lymphoma and T-cell lymphoma, B-cell lymphoma accounted nearly 85% of the lymphoma diagnoses and remaining 15% being T-cell lymphoma.
The photodynamic therapy market is set to grow at an impressive rate with a compounded annual growth rate (CAGR) of 5.7% during the forecast period from 2018 to 2026. As per the statistics provided by World Health Organization (WHO), currently 2 to 3 million non-melanoma and 132,000 melanoma skin cancer occurs throughout the globe annually.
The global immunocytokines market is growing significantly. In recent years monoclonal antibodies are being utilized to treat a wide array of cancer-related diseases. These monoclonal antibodies are mainly mono-specific encompassing similar immune cells which are copies of a single parent cell and are concentrated towards a definite cellular target. These antibodies due to its customizable environment, it can be used to only treat the tumor cells ineffective of the normal ones in the living body.
Interest in investing and developing in proton therapy has exponentially increased over the past few decades, including the clinical advantage of Bragg peak dose as against the conventional high-energy X-ray distribution of photons.
The fragment-based drug discovery (FBDD) market is expected to experience a CAGR of 11.7% during the forecast period of 2025 to 2033, driven by several key drivers that have revolutionized drug development methodologies. FBDD is a robust and innovative approach that has gained prominence in the pharmaceutical industry due to its ability to identify highly potent lead compounds with lower molecular weight, ultimately simplifying the chemical synthesis and optimization process.
Hypothyroidism as a syndrome was first recognized in the 1870s and its treatment with animal extracted thyroid was achieved in 1890s. Since 1927, synthetic thyroid hormone replacement therapy has been available, and in the recent years, there has been a minor shift in treatment away from levothyroxine. The currently popular treatment forms include use of liothyronine T3 as a monotherapy or even commonly combined with levothyroxine T3/T4. However, there is not current formulation of T3/T4 that completely replicates the natural hormone pattern released from human thyroid.
The circulating tumor cells prognostic technologies market is set to reach US$ 22.7 billion by 2029 from US$ 3.4 billion in 2019. The market is expected to expand at an impressive growth rate of 21% during the forecast period of 2021 to 2029. The lockdown due to the spread of covid 19 contained the movement of people and access to healthcare institutes except in case of emergency.
The oncology drugs market is a critical segment of the pharmaceutical industry, providing innovative solutions for the treatment of cancer. The market is driven by the increasing prevalence of cancer worldwide, advancements in technology, and the emergence of personalized medicine. The oncology drugs market is a highly competitive and dynamic market, with many companies focusing on the development of novel therapies to treat cancer. One of the primary drivers of the oncology drugs market is the increasing prevalence of cancer worldwide. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, accounting for approximately 9.6 million deaths in 2018. The rising incidence of cancer has led to an increased demand for innovative oncology drugs, driving the growth of the market.
The global oncology drugs market is expected to grow at a CAGR of 13% during the period of 2023 to 2031. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the oncology drugs market is the increasing use of immunotherapy. Immunotherapy involves the use of drugs that stimulate the body's immune system to attack cancer cells. Immunotherapy has shown promising results in the treatment of several types of cancer, including melanoma, lung cancer, and bladder cancer. The development of immunotherapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the oncology drugs market. Another trend in the oncology drugs market is the increasing focus on precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of the oncology drugs market.
The increasing focus on targeted therapies is also driving the growth of the oncology drugs market. Targeted therapies are drugs that are designed to target specific molecules that are involved in the growth and spread of cancer cells. Targeted therapies can be more effective than traditional chemotherapy, as they have fewer side effects and are more specific in their action. The development of targeted therapies requires the use of advanced drug discovery technologies, which has contributed to the growth of the oncology drugs market.
The increasing use of combination therapies is driving the growth of the oncology drugs market. Combination therapies involve the use of two or more drugs to treat cancer. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the oncology drugs market. The oncology drugs market is a critical segment of the pharmaceutical industry, providing innovative solutions for the treatment of cancer. The increasing prevalence of cancer worldwide, advancements in technology, and emerging trends in immunotherapy, precision medicine, targeted therapies, and combination therapies are expected to drive the growth of the oncology drugs market. As the demand for new and effective therapies continues to increase, the oncology drugs market is expected to remain a critical component of the pharmaceutical industry in the coming years. Companies that provide oncology drugs and related services are well-positioned to capitalize on this growing market.
